Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 30Neoplasm Metastasis 3Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Metastatic Castration-resistant Prostate Cancer 2Urologic Diseases 1Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Radiation Injuries 1Prostatic Diseases 1Prostate Cancer Metastatic 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oligometastatic Prostate Cancer 1Neoplasm Recurrence, Local 1Metastatic Hormone Sensitive Prostate Cancer 1Metastatic Castrate-sensitive Prostate Cancer 1Hormone Sensitive Prostate Cancer 1Genital Neoplasms, Male 1Gastrointestinal Diseases 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 3fludarabine 3aldesleukin 3Cyclophosphamide 3cabozantinib 2Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2CTLA-4 Antigen 2olaparib 1gallium 68 PSMA-11 1enfortumab vedotin 1darolutamide 1Therapeutics 1Radiosurgery 1Radiation Dose Hypofractionation 1Pluvicto 1Mitomycin 1Lutetium-177 1Lutetium 1Loperamide 1Geriatric Assessment 1Gemcitabine 1Fulvestrant 1Fluorouracil 1Fecal Microbiota Transplantation 1Exercise 1Continuous Positive Airway Pressure 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urogenital Neoplasms × Androgen Antagonists × 90 days × Clear all
NCT05067140 2026-05-05

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

Novartis

Phase 1/2 Active not recruiting
152 enrolled
Genitourinary

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡